These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 20383210

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [Abstract] [Full Text] [Related]

  • 3. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
    Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martínez-Chamorro C, Mateos-Mazón JJ, Ramírez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH.
    Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK.
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [Abstract] [Full Text] [Related]

  • 5. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
    Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK.
    Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Sancho JM, Duarte R, Medina L, Querol S, Marín P, Sureda A, en representación del Grupo de Trabajo de Movilización de la Sociedad Catalana de Hematología y Hemoterapia y de la Sociedad Catalano-Balear de Transfusión Sanguínea.
    Med Clin (Barc); 2016 Sep 02; 147(5):223.e1-223.e7. PubMed ID: 27374031
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
    Basak GW, Knopinska-Posluszny W, Matuszak M, Kisiel E, Hawrylecka D, Szmigielska-Kaplon A, Urbaniak-Kujda D, Dybko J, Zielinska P, Dabrowska-Iwanicka A, Werkun J, Rzepecki P, Wroblewska W, Wiktor-Jedrzejczak W.
    Ann Hematol; 2011 May 02; 90(5):557-68. PubMed ID: 20938660
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.
    Vox Sang; 2014 Nov 02; 107(4):407-15. PubMed ID: 25130876
    [Abstract] [Full Text] [Related]

  • 15. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M.
    J Clin Apher; 2013 Oct 02; 28(5):359-67. PubMed ID: 23765597
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT.
    Transfusion; 2011 May 02; 51(5):968-75. PubMed ID: 20880037
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
    Bakeer M, Zubair AC, Roy V.
    Cytotherapy; 2020 Jan 02; 22(1):16-20. PubMed ID: 31879152
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.